Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohnʼs disease population
- Schoepfer, Alain M.
- Vavricka, Stephan R.
- Binek, Janek
- Felley, Christian
- Geyer, Martin
- Manz, Michael
- Rogler, Gerhard
- de Saussure, Philippe
- Sauter, Bernhard
- Seibold, Frank
- Straumann, Alex
- Michetti, Pierre
Publication date
January 2010
DOI Publisher
Wiley ISSN
1078-0998 Citation count (estimate)
22Abstract
Switzerland was the first country to approve certolizumab pegol (Cimzia, CZP) for the treatment of patients with moderate to severe Crohn's disease (CD) in September 2007. This phase IV study aimed to evaluate the efficacy and safety of CZP in a Swiss multicenter cohort of practice-based patients
Add to ORKG